AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Saphnelo (anifrolumab) by Year
Saphnelo (anifrolumab) — Established RoW product sales ($M) ($M)
AstraZeneca Saphnelo (anifrolumab): $25M in FY2025, up 56.3% from a year earlier.
Latest, FY2025
25
Period ended Dec 31, 2025
Change on a year earlier
+56.3%
16 in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Saphnelo | 686 | 45 | 44 | 596 | 40 | 16 | n/m | n/m | 49 | 89 | 81 | 25 | 52 | 52”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Saphnelo (anifrolumab) — Established RoW product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25 | +56.3% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 16 | +60.0% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 10 | +233.3% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 3 | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up saphnelo (anifrolumab)
Cite this data
StockData. (2026). AstraZeneca Saphnelo (anifrolumab) ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-saphnelo-erow
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.